EMA QRD Appendix II Update: New MedDRA Standards for Section 4.8 (March 2026)

The EMA recently released version 7 of the QRD Appendix II. This document governs how we use MedDRA terminology in Section 4.8 of the Summary of Product Characteristics (SmPC). For any pharmaceutical company or CRO operating in the European market, this is a technical requirement that directly impacts regulatory approval times.

As the primary section for listing undesirable effects, Section 4.8 faces the heaviest scrutiny during a Quality Review of Documents (QRD) due to its focus on patient safety.

What Changed in the March 2026 Update?

The most significant shift in version 7 concerns the hierarchy of authority. The EMA now explicitly recognizes the MedDRA Introductory Guide as the final word. Should a conflict arise between Appendix templates and the latest MedDRA Guide, the Guide takes precedence.

Regulatory teams can no longer rely on static templates. Success now requires active cross-referencing between the clinical intent of MedDRA terms and the most current dictionary version.

Mandatory Sequence for System Organ Classes

The update also reinforces the mandatory order for System Organ Classes (SOC). This order is not just for clarity. It is becoming a requirement for electronic Product Information (ePI).

Regulatory databases and digital search tools expect a specific sequence when indexing safety data. In Greek translations, placing “Infections and infestations” or “Neoplasms” outside the EMA’s exact sequence can cause a document to fail technical validation.

Clinical Accuracy as a Regulatory Asset

Medical translation often suffers when MedDRA terms are treated as standard vocabulary. Instead, these terms function as precise codes for clinical realities.

Choosing an incorrect term for a lab finding in the “Investigations” SOC, for example, can fundamentally alter a drug’s safety profile. A Preferred Term (PT) carries a specific meaning that must remain intact when moving from the English master text to the Greek version.

For manufacturers of high-risk drugs or medical devices, a minor linguistic error in a safety table can trigger preventable comments from the National Organization for Medicines (EOF) or the EMA, delaying market entry.

Moving Toward Digital Compliance

The transition to version 7 aligns with the industry-wide move toward machine-readable data. By 2026, a Greek SmPC functions as a data set for indexing rather than just a document for clinical reading.

Correct MedDRA usage ensures a product’s safety profile is represented accurately within EudraVigilance. This level of precision protects the science behind the product from being lost in translation.

Does your current Greek SmPC reflect the March 2026 SOC ordering?

Checking this now prevents friction during your next submission.